Pfizer

Is Pfizer overvalued or undervalued?

As of December 12, 2023, Pfizer is considered very expensive and overvalued with a PE ratio of 41.15 and an EV to EBITDA of 32.17, significantly higher than peers like Sun Pharma and Cipla, despite outperforming the Sensex in the short term.

As of 12 December 2023, Pfizer's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 41.15, an EV to EBITDA of 32.17, and a PEG ratio of 2.56, all of which are substantially higher than many of its peers.<BR><BR>In comparison, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla stands at a much lower PE of 22.99 and an EV to EBITDA of 15.93, showcasing that Pfizer's valuation metrics are considerably elevated. Additionally, Pfizer's recent stock performance has outpaced the Sensex over the past month and year, with returns of 32.93% and 14.79%, respectively, although it still lags behind the Sensex over longer periods.

What does Pfizer do?

Pfizer Limited is a large-cap pharmaceutical company in India, involved in manufacturing, marketing, and exporting pharmaceutical products. As of March 2025, it reported net sales of 592 Cr and a net profit of 331 Cr, with a market cap of Rs 26,116 Cr.

Overview:<BR>Pfizer Limited is engaged in the manufacturing, marketing, trading, and export of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Large Cap company.<BR><BR>History:<BR>Pfizer Limited was incorporated in India and has established itself as a pioneer in clinical research within the country. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 592 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 331 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 26,116 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 42.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.60%<BR>- Debt Equity: -0.60<BR>- Return on Equity: 16.88%<BR>- Price to Book: 7.08<BR><BR>Contact Details:<BR>Address: The Capital 1802/1901 Plot-C70, G Bl Bandra Kurla Cpx Bandra-E Mumbai Maharashtra : 400051<BR>Tel: 91-22-66932000<BR>Email: contactus.india@pfizer.com<BR>Website: http://www.pfizerindia.com

Has Pfizer declared dividend?

Yes, Pfizer has declared a dividend of 350%, amounting to 35 per share, with an ex-date of August 21, 2024. The dividend yield is 0.6%, and total returns over various periods have shown positive performance, particularly in the long term.

Pfizer Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 350%<BR>- Amount per share: 35<BR>- Ex-date: 21 Aug 24<BR><BR>Dividend Yield: 0.6%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 9.39%, with no dividend return, resulting in a total return of 9.39%.<BR><BR>Over the past year, the price return was 17.0%, with a dividend return of 0.71%, leading to a total return of 17.71%.<BR><BR>In the 2-year period, the price return was 44.62%, with a dividend return of 1.04%, culminating in a total return of 45.66%.<BR><BR>For the 3-year period, the price return was 36.06%, with a dividend return of 2.55%, resulting in a total return of 38.61%.<BR><BR>In the 4-year period, the price return was 10.34%, with a dividend return of 1.97%, leading to a total return of 12.31%.<BR><BR>Over the last 5 years, the price return was 39.69%, with a dividend return of 2.87%, resulting in a total return of 42.56%.<BR><BR>Overall, Pfizer's recent dividend declaration reflects a significant return to shareholders, and the total returns over various periods indicate a generally positive performance, particularly in the longer term.

Who are the peers of the Pfizer?

Pfizer's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Emcure Pharma, Wockhardt, OneSource Specialty, ERIS Lifescience, and Alembic Pharma. In terms of performance, Wockhardt has the highest 1-year return at 175.09%, while Pfizer's return is 20.11%.

Peers: The peers of Pfizer are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Emcure Pharma, Wockhardt, OneSource Speci., ERIS Lifescience, and Alembic Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Emcure Pharma, OneSource Speci., ERIS Lifescience, and Alembic Pharma, while Average management risk is found at Wockhardt. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and OneSource Speci., while below average growth is noted for Divi's Lab., Pfizer, Torrent Pharma, Emcure Pharma, ERIS Lifescience, and Alembic Pharma. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Pfizer, and ERIS Lifescience, while good capital structure is noted for Torrent Pharma and Emcure Pharma, and below average capital structure is found at Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 175.09%, while the peer with the lowest is Emcure Pharma, which has no available data. Pfizer's 1-year return is 20.11%, which is significantly lower than Wockhardt's but higher than Emcure Pharma's. Additionally, Emcure Pharma and Alembic Pharma have negative six-month returns.

Who are in the management team of Pfizer?

As of March 2023, Pfizer's management team includes Prajeet Nair (Company Secretary), Milind Anil Patil (Executive Director, Finance), Meenakshi Nevatia (Managing Director), and several independent directors, including Pradip P Shah (Chairman). The team combines executive and independent leadership for effective governance.

As of March 2023, the management team of Pfizer includes the following individuals:<BR><BR>1. Prajeet Nair - Company Secretary & Compliance Officer<BR>2. Uday Khanna - Independent Director<BR>3. Sunil Lalbhai - Independent Director<BR>4. Milind Anil Patil - Executive Director (Finance)<BR>5. Meena Ganesh - Independent Director<BR>6. Samir Kazi - Executive Director<BR>7. Pradip P Shah - Chairman & Independent Director<BR>8. Meenakshi Nevatia - Managing Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and operational leadership of the company.

Who are the top shareholders of the Pfizer?

The top shareholders of Pfizer include Pfizer East India B V with 39.75%, mutual funds holding 11.59%, individual investors at 12.34%, and Nippon Life India Trustee Ltd as the largest public shareholder with 4.17%. Foreign Institutional Investors (FIIs) hold 2.18% of the shares.

The top shareholders of Pfizer include Pfizer East India B V, which holds the largest share at 39.75%. Other significant shareholders include mutual funds, which collectively hold 11.59% through 24 schemes, and individual investors, who account for 12.34% of the shares. Additionally, Nippon Life India Trustee Ltd is the highest public shareholder with a 4.17% stake. Foreign Institutional Investors (FIIs) hold 2.18% of the shares through 67 different entities.

How big is Pfizer?

As of 24th July, Pfizer Ltd. has a market capitalization of 24,201.00 Cr and reported net sales of 2,281.35 Cr and a net profit of 767.60 Cr over the latest four quarters. Data for Shareholder's Funds and Total Assets is unavailable.

As of 24th July, <BR><BR>Market Cap: Pfizer Ltd. has a market capitalization of 24,201.00 Cr and is classified as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of net sales for the latest four quarters is 2,281.35 Cr, while the sum of net profit for the same period is 767.60 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period. However, data for Shareholder's Funds and Total Assets is unavailable.

When is the next results date for Pfizer?

The next results date for Pfizer is November 12, 2025.

The next results date for Pfizer is scheduled for November 12, 2025.

How has been the historical performance of Pfizer?

Pfizer's historical performance shows fluctuating net sales, increasing from 681.70 Cr in 2008 to 772.27 Cr in 2009, but profitability declined, with profit after tax dropping from 299.58 Cr to 137.12 Cr due to rising expenditures. Despite sales growth, the company faced challenges in managing costs, leading to reduced profit margins.

Answer:<BR>The historical performance of Pfizer shows a trend of fluctuating net sales and profits over the years reported.<BR><BR>Breakdown:<BR>Pfizer's net sales increased from 681.70 Cr in November 2008 to 772.27 Cr in November 2009, indicating a positive growth trend. Other operating income also rose slightly from 22.90 Cr in November 2008 to 24.37 Cr in November 2009. Total operating income followed this upward trajectory, reaching 796.64 Cr in November 2009, up from 704.60 Cr the previous year. However, total expenditure increased significantly from 552.36 Cr in November 2008 to 638.47 Cr in November 2009, leading to an operating profit (PBDIT) of 229.22 Cr in November 2009, which was a modest increase from 222.35 Cr in November 2008. The profit before tax saw a notable decline from 419.13 Cr in November 2008 to 210.01 Cr in November 2009, and consequently, profit after tax also decreased from 299.58 Cr to 137.12 Cr in the same period. This resulted in a drop in earnings per share from 100.4 to 45.95. The operating profit margin and profit after tax margin also decreased, reflecting a decline in profitability. Overall, while Pfizer experienced growth in sales, the profitability metrics suggest challenges in managing costs effectively during this period.

Is Pfizer technically bullish or bearish?

As of December 1, 2025, Pfizer's technical stance is mildly bearish due to bearish MACD, Bollinger Bands, and KST indicators on weekly and monthly charts, despite a mildly bullish signal from daily moving averages.

As of 1 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current technical stance for Pfizer is mildly bearish. Key indicators driving this stance include a bearish MACD on both weekly and monthly time frames, bearish Bollinger Bands across both time frames, and a bearish KST on the weekly chart. The daily moving averages show a mildly bullish signal, but this is overshadowed by the overall bearish sentiment in the weekly and monthly indicators. Additionally, the stock has underperformed compared to the Sensex across multiple time frames, further supporting the bearish outlook.

Are Pfizer Ltd. latest results good or bad?

Pfizer Ltd.'s latest results show strong revenue growth with net sales up 6.52% quarter-on-quarter, but net profit declined by 1.42% from the previous quarter, raising concerns about profitability sustainability. Overall, the results are mixed, highlighting both positive revenue trends and challenges in maintaining profit margins.

Pfizer Ltd.'s latest results present a mixed picture. In Q2 FY26, the company reported net sales of ₹642.34 crores, which reflects a healthy increase of 6.52% quarter-on-quarter and 9.13% year-on-year. This indicates solid revenue growth and marks the highest quarterly revenue figure in recent periods.<BR><BR>However, the net profit for the same quarter was ₹189.02 crores, which represents a slight decline of 1.42% compared to the previous quarter, although it shows a significant year-on-year improvement of 19.37%. This decline in net profit raises concerns about the sustainability of the company's profitability, especially considering the pressures on margins.<BR><BR>The operating margin improved to 35.80%, indicating better cost management, but the profit after tax margin contracted, suggesting some challenges in maintaining profitability amidst rising costs. Additionally, the significant drop in other income further highlights the company's reliance on its core pharmaceutical operations for profitability.<BR><BR>Overall, while Pfizer Ltd. demonstrates strong revenue growth and maintains a robust capital efficiency profile, the decline in net profit and the pressures on margins indicate that the results are not entirely positive. Investors may need to weigh these factors carefully when assessing the company's performance and future outlook.

Should I buy, sell or hold Pfizer Ltd.?

Which are the latest news on Pfizer?

Why is Pfizer Ltd. falling/rising?

As of 17-Mar, Pfizer Ltd.'s stock price is currently at 4,729.35, reflecting a decline of -0.42% and underperforming its sector. Despite a significant increase in delivery volume and a high dividend yield, the stock has shown a consistent downward trend over the past month.

As of 17-Mar, Pfizer Ltd.'s stock price is falling, currently at 4,729.35, which reflects a change of -19.9 or -0.42%. The stock has underperformed its sector today by -0.95%. Additionally, it is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a downward trend in its price performance. Over the past week, the stock has decreased by 1.86%, while the benchmark Sensex has fallen by 2.73%, suggesting that Pfizer has performed relatively better than the broader market in that timeframe. However, over the past month, Pfizer's stock has declined by 6.39%, compared to a larger drop of 8.84% in the Sensex, indicating a consistent downward movement.<BR><BR>Despite the falling price, there are some positive indicators such as a significant increase in delivery volume, which rose by 151.1% against the 5-day average, and a high dividend yield of 3.52% at the current price. These factors may suggest increased investor interest, but they have not yet translated into a price increase. Overall, the combination of underperformance relative to moving averages and sector performance contributes to the current decline in Pfizer Ltd.'s stock price.

Why is Pfizer Ltd. falling/rising?

As of 18-Mar, Pfizer Ltd.'s stock price is rising to 4,822.85, driven by strong relative performance and positive trading momentum, despite a recent monthly decline. The stock offers an attractive dividend yield of 3.5% and has shown resilience with an 18.50% return over the past year, although investor participation has decreased.

As of 18-Mar, Pfizer Ltd.'s stock price is rising, currently at 4,822.85, reflecting a change of 93.5 (1.98%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector today by 1.71%, indicating strong relative performance. Additionally, it reached an intraday high of Rs 4850, which is a 2.55% increase, suggesting positive momentum in trading.<BR><BR>Despite a decline of 6.35% over the past month, the stock has shown resilience with an 18.50% return over the last year, significantly outperforming the broader market, which returned only 1.86% during the same period. Furthermore, the company maintains a high management efficiency with a return on equity (ROE) of 18.68% and a low debt-to-equity ratio, which can instill investor confidence.<BR><BR>Moreover, the stock's high dividend yield of 3.5% at the current price makes it attractive to income-focused investors. However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 64.13% compared to the 5-day average, which could indicate some caution among investors. Overall, the combination of strong short-term performance, attractive dividend yield, and solid management metrics contributes to the stock's rising price.

Why is Pfizer Ltd. falling/rising?

As of 19-Mar, Pfizer Ltd.'s stock price is falling to 4,715.05, down 2.24%, reflecting broader sector declines and reduced investor interest. Despite a positive annual return of 15.60%, concerns over long-term growth and high valuation are pressuring the stock.

As of 19-Mar, Pfizer Ltd.'s stock price is falling, currently at 4,715.05, which reflects a decrease of 107.8 points or 2.24%. This decline is consistent with the overall performance of the Pharmaceuticals & Drugs sector, which has seen a drop of 2.13%. Additionally, the stock's performance today has been described as inline with the sector, indicating that external market conditions are contributing to the downward trend.<BR><BR>The stock has also experienced a significant decline in investor participation, with delivery volume dropping by 55.67% compared to the 5-day average. This reduced interest from investors may further pressure the stock price. Furthermore, while the stock has shown a positive return of 15.60% over the past year, its recent performance over shorter periods has been less favorable, with a 5.57% decline over the last month and a year-to-date decrease of 5.37%.<BR><BR>Despite having a high dividend yield of 3.45% and strong management efficiency indicated by a high return on equity (ROE) of 18.68%, the company faces challenges such as poor long-term growth, with net sales growing at an annual rate of only 2.39% over the last five years. The stock's valuation is also considered expensive, trading at a price-to-book value of 5.6, which may deter potential investors.<BR><BR>Overall, the combination of sector-wide declines, reduced investor participation, and concerns regarding long-term growth prospects are contributing to the falling stock price of Pfizer Ltd.

Why is Pfizer Ltd. falling/rising?

As of 20-Mar, Pfizer Ltd.'s stock price is rising to 4,760.80, reflecting a 0.8% increase. Despite recent challenges like declining investor participation and underperformance relative to its sector, the stock shows strong year-on-year returns and a high dividend yield.

As of 20-Mar, Pfizer Ltd.'s stock price is rising, currently at 4,760.80, reflecting an increase of 37.7 points or 0.8%. This rise can be attributed to several factors. Firstly, the stock has outperformed the Sensex over the past week, gaining 3.17% while the benchmark has slightly declined by 0.04%. Additionally, despite a negative performance over the past month with a decrease of 3.58%, the stock has shown resilience with a significant year-on-year return of 15.88%, which is much higher than the market's average return of 0.76%.<BR><BR>Furthermore, the stock boasts a high dividend yield of 3.5%, which can attract income-focused investors. The company also demonstrates strong management efficiency with a high return on equity (ROE) of 18.68% and maintains a low debt-to-equity ratio, indicating financial stability. However, it is important to note that the stock is currently underperforming its sector by 0.9% today and has experienced a significant drop in investor participation, with delivery volume falling by 75.59% against the 5-day average.<BR><BR>In summary, while Pfizer Ltd. is experiencing a rise in stock price, it faces challenges such as declining investor participation and underperformance relative to its sector, which could impact its future performance.

Why is Pfizer Ltd. falling/rising?

As of 23-Mar, Pfizer Ltd. is experiencing a decline in its stock price, currently at 4,538.50, reflecting a significant drop and high volatility. The stock has underperformed its sector and benchmark indices, with poor short-term performance and declining investor interest contributing to its bearish trend.

As of 23-Mar, Pfizer Ltd. is experiencing a decline in its stock price, currently at 4,538.50, which reflects a change of -233.05 (-4.88%). The stock has underperformed its sector by -1.31% today and opened with a loss of -2.65%. Throughout the day, it reached a high of Rs 4995 but also touched a low of Rs 4525.9, indicating significant volatility with an intraday volatility of 8.42%.<BR><BR>The stock's performance over the past week shows a decline of -4.44%, which is worse than the benchmark Sensex's drop of -3.72%. Over the past month, Pfizer's stock has fallen by -10.50%, while the Sensex has decreased by -12.72%. Year-to-date, the stock is down -8.91%, compared to the Sensex's -14.70%. Despite a positive annual return of +9.81% over the last year, the stock's long-term growth prospects appear poor, with net sales growing at an annual rate of only 2.39% and operating profit at 7.42% over the last five years.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. The pharmaceutical sector has also seen a decline of -3.58%, contributing to the negative sentiment surrounding Pfizer. Furthermore, there has been a significant drop in investor participation, with delivery volume falling by -64.92% against the five-day average.<BR><BR>Overall, the combination of poor short-term performance, high volatility, and declining investor interest are key factors contributing to the falling stock price of Pfizer Ltd.

Why is Pfizer Ltd. falling/rising?

As of 24-Mar, Pfizer Ltd.'s stock price is rising to 4,657.00, up 2.31%, driven by strong performance metrics, a high dividend yield of 3.64%, and resilience against market challenges, despite concerns about long-term growth. The stock has outperformed its sector and shows strong management efficiency, contributing to positive investor sentiment.

As of 24-Mar, Pfizer Ltd.'s stock price is rising, currently at 4,657.00, with a change of 105.15 (2.31%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.19% today, indicating a positive performance relative to its peers. Additionally, the stock reached an intraday high of Rs 4699.75, reflecting a 3.25% increase during the trading session.<BR><BR>Despite the stock trading lower than its moving averages over various periods, the high dividend yield of 3.64% at the current price may attract investors seeking income, contributing to the upward price movement. Furthermore, Pfizer Ltd. has demonstrated strong management efficiency with a high return on equity (ROE) of 18.68% and a low debt-to-equity ratio, which suggests financial stability.<BR><BR>Moreover, the stock has shown resilience in the face of broader market challenges, generating a return of 13.63% over the past year, while the market (BSE500) has experienced negative returns of -2.67%. This market-beating performance indicates investor confidence in Pfizer Ltd., despite some concerns regarding long-term growth and flat results in recent financial periods. Overall, the combination of positive performance metrics and investor sentiment appears to be driving the stock's rise.

Why is Pfizer Ltd. falling/rising?

As of 25-Mar, Pfizer Ltd.'s stock price is rising to 4,741.00, driven by consecutive gains, increased investor interest, and strong financial metrics, including a high dividend yield and solid returns compared to the broader market.

As of 25-Mar, Pfizer Ltd.'s stock price is rising, currently at 4,741.00, with a change of 76.2 (1.63%) upward. This increase can be attributed to several factors. Firstly, the stock has shown a consecutive gain over the last two days, rising by 4.16% during this period. Additionally, the stock reached an intraday high of Rs 4874.7, reflecting a 4.5% increase at its peak today.<BR><BR>Investor participation has also improved, with delivery volume on 24 March rising by 43.71% compared to the 5-day average, indicating heightened interest among investors. Furthermore, the stock boasts a high dividend yield of 3.54%, which can attract income-focused investors.<BR><BR>Despite some underperformance against the sector today, the stock has outperformed the broader market over the past year, generating a return of 15.94% while the market (BSE500) has seen negative returns of -0.34%. This market-beating performance, combined with a high return on equity (ROE) of 18.68% and a low debt-to-equity ratio, suggests strong management efficiency and financial health, contributing to the stock's upward movement. <BR><BR>Overall, these factors collectively support the rise in Pfizer Ltd.'s stock price.